

Press Release

Contact:

INVESTOR RELATIONS

Ashish Girotra
ashishg@drreddys.com
(Ph: +1 6093756145)

MEDIA RELATIONS

Lori McCreary
lmccreary@drreddys.com
(Ph: +1 6093752955)

107 College Road East
Princeton, NJ 08540

www.promiuspharma.com

Promius Pharma Announces Migraine Presentations at the 60th Annual Scientific Meeting of the American Headache Society

Princeton, NJ, USA. June 27, 2018 – Promius Pharma LLC announced today its presentations for the 60th Annual Scientific Meeting of the American Headache Society (AHS) in San Francisco, CA, June 28 – July 1, 2018.

Promius will present 6 posters at the AHS:

- Menstrual Migraine and Associated Pain Onset, Intensity and Interference: Results from the 2017 Migraine in America Symptoms and Treatment (MAST) Study
- Most Bothersome Migraine Symptom and Associated Burden: Results from 2017 Migraine in America Symptoms and Treatment (MAST) Study
- Efficacy, Tolerability, and Safety of Repeat Dosing with DFN-11, a Low-Dose (3 mg) Sumatriptan Injection, in Episodic Migraine: An Open-Label Extension of RESTOR
- Tolerability of DFN-11, Low Dose (3 mg) Sumatriptan Injection: Focus on Triptan Sensations and Injection Site Reactions in the RESTOR Episodic Migraine Study
- Pharmacokinetics of Intranasal Sumatriptan With and Without the Effect of Dodecyl Maltoside
- DFN-02 Nasal Spray (Sumatriptan 10 mg + Permeation Enhancer) in the Acute Treatment of Migraine: Better Sustained Pain Freedom and Total Migraine Freedom with Lower Rescue Medication Use Compared with Placebo

“Promius has made significant strides in better understanding the needs of headache patients and advancing a relevant pipeline for the acute treatment of migraine,” said Alan M. Rapoport, M.D., Clinical Professor of Neurology at the David Geffen School of Medicine at UCLA in Los Angeles, and former President of the International Headache Society. “MAST data highlights the unmet needs in migraine. DFN-02 is a promising option being investigated for the acute treatment of migraine and, if approved, it should help meet some of these needs.”

Additionally, Promius will deliver 4 platform presentations:

- Low-Dose (3 mg) Sumatriptan Injection (DFN-11) Efficacy, Tolerability, and Safety in Episodic Migraine: RESTOR, a Randomized, Double-Blind, Placebo-Controlled Study
- Assessing of Unmet Treatment Needs and Associated Disability Among Persons with Migraine: Results from 2017 MAST Study
- Triptan Use and Discontinuation Among a Population Sample of Persons with Migraine: Results from 2017 MAST Study

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganisation, including related integration issues. The company assumes no obligation to update any information contained herein.

Press Release	Contact:
INVESTOR RELATIONS Ashish Girotra ashishg@drreddys.com (Ph: +1 6093756145)	MEDIA RELATIONS Lori McCreary lmccreary@drreddys.com (Ph: +1 6093752955)

107 College Road East
Princeton, NJ 08540
www.promiuspharma.com

- DFN-02 Nasal Spray (Sumatriptan 10 mg + Permeation Enhancer) in the Acute Treatment of Migraine: Better Sustained Pain Freedom and Total Migraine Freedom with Lower Rescue Medication Use Compared with Placebo

“Scientific research is the lifeblood of our mission to address the unmet needs of migraine patients,” said Sagar Munjal, Chief Medical Officer, Promius Pharma. “We’re excited to share the results of our team’s work at the 2018 AHS Annual Scientific Meeting with additional clinical data on the efficacy and safety of DFN-11. In addition, we are pleased to show promising data on investigational agents in our pipeline. Receiving continuous opportunities to present our research is a testimony to our scientific rigor in developing meaningful solutions to patient needs.”

About the MAST Study

The MAST Study addresses gaps in knowledge due to changing demographics and treatment options in the US migraine community. MAST was designed to shed light on the current state of migraine symptom characteristics, including the most bothersome migraine symptoms and how pain interferes with daily functioning.

About DFN-02

DFN-02 is a novel intranasal spray formulation, currently patented in 11 countries (total of 13 issued patents), composed of sumatriptan 10 mg and Aegis Therapeutics, LLC permeation-enhancing excipient known as Intravail®. This formulation of DFN-02 allows sumatriptan to be rapidly absorbed into the systemic circulation, and it exhibits pharmacokinetics comparable to subcutaneously administered sumatriptan. DFN-02 is a novel investigational intranasal formulation in development for the acute treatment of migraine with or without aura.

About Promius Pharma LLC

Promius Pharma is a wholly owned subsidiary of Dr. Reddy’s Laboratories, one of the largest and most respected pharmaceutical companies in the world. With a robust commercial infrastructure and extensive research and development capabilities through its parent company, Promius Pharma is committed to bringing new products to market that meet patients’ needs in dermatology and neurology. For more information, visit www.promiuspharma.com.

Contact information:

Promius Pharma, LLC
107 College Rd E
Princeton, NJ 08540
www.promiuspharma.com

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words “may”, “will”, “should”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “continue” and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganisation, including related integration issues. The company assumes no obligation to update any information contained herein.

Press Release

Contact:

INVESTOR RELATIONS

Ashish Girotra
ashishg@drreddys.com
(Ph: +1 6093756145)

MEDIA RELATIONS

Lori McCreary
lmccreary@drreddys.com
(Ph: +1 6093752955)

107 College Road East
Princeton, NJ 08540
www.promiuspharma.com

Investor Relations:
Ashish Girotra (USA)
ashishg@drreddys.com
+1 (609) 375-6145

Media Relations:
Lori McCreary (USA)
lmccreary@drreddys.com
+1 (609) 375-2955

Copyright 2018 Promius Pharma, LLC

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganisation, including related integration issues. The company assumes no obligation to update any information contained herein.